Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder

Timothy E. Wilens, Jeffrey H. Newcorn, Christopher J. Kratochvil, Haitao Gao, Christine K. Thomason, Ann K. Rogers, Peter D. Feldman, Louise R. Levine

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Objective: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. Study design: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. Results: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. Conclusions: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns.

Original languageEnglish
Pages (from-to)112-119
Number of pages8
JournalJournal of Pediatrics
Issue number1
StatePublished - Jul 2006
Externally publishedYes


Dive into the research topics of 'Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder'. Together they form a unique fingerprint.

Cite this